ArticleScientific reports2020
The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 64 citations in OpenAlex.
- Activating a patient-relevant pathogenic variant of a genetically defined heart disease in a humanized pig model.Lab animal · 2026Article
- Tracing the pathogenic PLN p.(Arg14del) variant across the globe; more than just a local curiosity.Journal of cardiovascular translational research · 2026Article
- Microprotein, macro-effect: DWORF as a therapeutic strategy in heart failure.Frontiers in cell and developmental biology · 2026Review
- Calcium handling remodeling in dilated cardiomyopathy: From molecular mechanisms to targeted therapies.Channels (Austin, Tex.) · 2025Review
- In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment.Cardiovascular research · 2025Article
- Cardiac remodeling pathways do not accelerate disease onset and severity in a mouse model of PLN-R14del cardiomyopathy.Scientific reports · 2025Article
- Functional analysis and transcriptional profiling of non-coding RNAs in yeast.The Biochemical journal · 2025Review
- Living myocardial slices retain patient-specific features: Insights into etiology and therapeutic history.JHLT open · 2025Article
- Elevated plasma bile acids coincide with cardiac stress and inflammation in young Cyp2c70Pediatric research · 2025Article
- Identification of disease-specific pathways and modifiers in phospholamban R14del cardiomyopathy: rationale, design and baseline characteristics of DECIPHER-PLN cohort.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2025Article
- Genetic landscape of phospholamban cardiomyopathies.Frontiers in cell and developmental biology · 2025Review
- Altered endoplasmic reticulum calcium loading in human PLN-R14del cardiomyopathy.Frontiers in cell and developmental biology · 2025Article
- Cardiac Applications of CRISPR/AAV-Mediated Precise Genome Editing.bioRxiv : the preprint server for biology · 2024Article
- The phospholamban R14del generates pathogenic aggregates by impairing autophagosome-lysosome fusion.Cellular and molecular life sciences : CMLS · 2024Article
- Reassessing the Mechanisms of PLN-R14del Cardiomyopathy: From Calcium Dysregulation to S/ER Malformation.JACC. Basic to translational science · 2024Review
- In Vivo Approaches to Understand Arrhythmogenic Cardiomyopathy: Perspectives on Animal Models.Cells · 2024Review
- Review
- Long-term reliability of the phospholamban (PLN) p.(Arg14del) risk model in predicting major ventricular arrhythmia: a landmark study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Article
- Deletion of DWORF does not affect cardiac function in aging and in PLN-R14del cardiomyopathy.American journal of physiology. Heart and circulatory physiology · 2024Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 5 institutions in 1 country.
Tim R EijgenraamDepartment of Experimental Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Bastiaan J BoukensDepartment of Medical Biology, University of Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Cornelis J BoogerdHubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center Utrecht, Utrecht, the Netherlands.
E Marloes SchoutenDepartment of Experimental Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Cees W A van de KolkCentral Animal Facility, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Nienke M StegeDepartment of Experimental Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Wouter P Te RijdtDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Edgar T HoorntjeDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Paul A van der ZwaagDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Eva van RooijHubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center Utrecht, Utrecht, the Netherlands.
J Peter van TintelenDepartment of Genetics, University of Utrecht, University Medical Center Utrecht, Utrecht, the Netherlands.
Maarten P van den BergDepartment of Experimental Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Peter van der MeerDepartment of Experimental Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Jolanda van der VeldenDepartment of Physiology, University of Amsterdam, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
Herman H W SilljéDepartment of Experimental Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Rudolf A de BoerDepartment of Experimental Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. r.a.de.boer@umcg.nl.
University of Groningen · NLUniversity Medical Center Groningen · NLRoyal Netherlands Academy of Arts and Sciences · NLUniversity of Amsterdam · NLUtrecht University · NL
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phospholamban (PLN) plays a role in cardiomyocyte calcium handling as primary inhibitor of sarco/endoplasmic reticulum Ca
Indexed as
MutationAnimalsCalcium-Binding ProteinsCardiomyopathiesEplerenoneHeart FailureMetoprololMicePhenotypePhospholambanRiskTreatment FailureCalcium-Binding ProteinsEplerenoneMetoprololPhospholamban
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.